Concord Biotech Q4 profit slides 37%, margins shrink; declares ₹7.55 dividend

Concord Biotech on Friday, May 29, reported a 36.8% drop in fourth-quarter earnings, with net profit falling to ₹88.8 crore from ₹140.4 crore in the corresponding quarter last year, impacted by lower revenue and margin contraction.The R&D-driven biopharmaceutical company said its revenue from operations declined 24.1% to ₹326.1 crore compared with ₹429.9 crore a year ago.

Earnings before interest, taxes, depreciation, and amortisation (EBITDA) for the quarter fell 37.8% year-on-year to ₹118.5 crore, while the EBITDA margin narrowed to 36.4% from 44.3% in the year-ago period.
The board recommended a dividend of ₹7.55 per equity share of face value ₹1 each for FY26, subject to shareholder approval, at the upcoming annual general meeting.The company has fixed July 24, 2026, as the record date for determining eligible shareholders for the dividend payout.

ALSO READ | Inox Wind Q4 profit falls amid margin pressure; guides for strong FY27 growth

Ahead of the results announcement, shares of Concord Biotech closed 4.46% lower at ₹1,050.60 on the NSE on Friday, May 29.

ALSO READ | SEBI imposes ₹29-cr penalties on Suzlon Energy & key execs in OMS slump sale case